Global Blood Therapeutics, an early-stage biotech developing a small molecule therapy for sickle cell disease, filed on Wednesday with the SEC to raise up to $115 million in an initial public offering.
The South San Francisco, CA-based company, which was founded in 2011, plans to list on the NASDAQ under the symbol GBT. Global Blood Therapeutics initially filed confidentially on March 19, 2015. Morgan Stanley and Goldman Sachs are the joint bookrunners on the deal. No pricing terms were disclosed.
